Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Owing to a lack of effective treatments, patients with metastatic disease have a median survival time of 6–12 months. We recently demonstrated that the Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-coding RNA (SAMMSON) is essential for UM cell survival and that antisense oligonucleotide (ASO)-mediated silencing of SAMMSON impaired cell viability and tumor growth in vitro and in vivo. By screening a library of 2911 clinical stage compounds, we identified the mammalian target of rapamycin (mTOR) inhibitor GDC-0349 to synergize with SAMMSON inhibition in UM. Mechanistic studies revealed that mTOR inhibition enhanced uptake and reduced lysosomal accumulation of lipid complexed SAMMSON ASOs, improving SAMMSON knockdown and further decreasing UM cell viability. We found mTOR inhibition to also enhance target knockdown in other cancer cell lines as well as normal cells when combined with lipid nanoparticle complexed or encapsulated ASOs or small interfering RNAs (siRNAs). Our results are relevant to nucleic acid treatment in general and highlight the potential of mTOR inhibition to enhance ASO and siRNA-mediated target knockdown.
Get full access to this article
View all access options for this article.
References
1.
SharmaA, SteiM, FröhlichH, HolzF, LoefflerK and Herwig-CarlM. (2018). Genetic and epigenetic insights into uveal melanoma. Clin Genet, 93:952–961.
2.
ParkJ, DiefenbachR, JoshuaA, KeffordR, CarlinoM and RizosH. (2018). Oncogenic signaling in uveal melanoma. Pigment Cell Melanoma Res, 31:661–672.
3.
YangJ, MansonD, MarrB and CarvajalRD. (2018). Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol, 10:1–17.
LucenaE, GoldembergD, ThulerL and de MeloA. (2020). Epidemiology of uveal melanoma in Brazil. Int J Retina Vitreous, 6:1–8.
6.
BolK, DoniaM, HeegaardS, KiilgaardJ and SvaneI. (2020). Genetic biomarkers in melanoma of the ocular region: what the medical oncologist should know. Int J Mol Sci, 21:5214–5231.
7.
WoodmanS (2012) Metastatic uveal melanoma. Cancer J, 18:148–152.
8.
RodríguezA, Dueñas-GonzalezA and Delgado-PelayoS. (2016). Clinical presentation and management of uveal melanoma. Mol Clin Oncol, 5:675–677.
9.
KrantzB, DaveN, KomatsubaraK and CarvajalR. (2017). Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol, 11:279–289.
10.
de OliveiraJ, OliveiraL, MathiasC, PedrosaG, LemosD, Salviano-SilvaA, JucoskiT, Lobo-AlvesSC, ZambaldeEP, CipollaGA and Gradia.DF (2019). Long non-coding RNAs in cancer: another layer of complexity. J Gene Med, 21:e3065.
11.
LeucciE, VendraminR, SpinazziM, LauretteP, FiersM, WoutersJ, RadaelliE, EyckermanS, LeonelliC, et al. (2016). Melanoma addiction to the long non-coding RNA SAMMSON. Nature, 531:518–522.
12.
DewaeleS, DelhayeL, De PaepeB, De BonyE, De WildeJ, VanderheydenK, AnckaertJ, YigitN, Van denEyndeE, et al. (2021). The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival. Oncogene, 41:15–25.
WangF, ZuroskeT and WattsJ. (2020). RNA therapeutics on the rise. Nat Rev Drug Discov, 19:441–442.
15.
DhuriK, BechtoldC, QuijanoE, PhamH, GuptaA, VikramA and Bahal.R (2020). Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med, 9:2004.
16.
JulianoR. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res, 44:6518–6548.
17.
ChernikovI, VlassovV and Chernolovskaya.E (2019). Current development of siRNA bioconjugates: from research to the clinic. Front Pharmacol, 10:444.
18.
SteinC, HansenJ, LaiJ, WuS, VoskresenskiyA, HogA, WormJ, HedtjärnM, SouleimanianN, et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res, 38:e3.
19.
WattA, SwayzeG, SwayzeE and FreierS. (2020). Likelihood of nonspecific activity of gapmer antisense oligonucleotides is associated with relative hybridization free energy. Nucleic Acid Ther, 30:215–228.
20.
LinnaneE, DaveyP, ZhangP, PuriS, EdbrookeM, ChiarparinE, RevenkoA, Robert MacleodA, NormanJ and RossS. (2019). Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res, 47:4375–4392.
VermeulenL, BransT, De SmedtS, RemautK and BraeckmansK. (2018). Methodologies to investigate intracellular barriers for nucleic acid delivery in non-viral gene therapy. Nano Today, 21:74–90.
23.
KristenA, Ajroud-DrissS, ConceicaoI, GorevicP, KyriakidesT and ObiciL. (2018). Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegerat Dis Manage, 9:5–23
24.
AkincA, MaierMA, ManoharanM, FitzgeraldK, JayaramanM, BarrosS, AnsellS, DuX, HopeM, et al. (2019). The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol, 14:1084–1087.
25.
CullisP and Hope.M (2017). Lipid nanoparticle systems for enabling gene therapies. Mol Ther, 25:1467.
26.
JorisF, De BackerL, Van de VyverT, BastiancichC, De SmedtS and RaemdonckK. (2018). Repurposing cationic amphiphilic drugs as adjuvants to induce lysosomal siRNA escape in nanogel transfected cells. J Control Release, 269:266–276.
27.
Du RietzH, HedlundH, WilhelmsonS, NordenfeltP and WittrupA. (2020). Imaging small molecule-induced endosomal escape of siRNA. Nat Commun, 11:1–17.
28.
Van de VyverT, BogaertB, De BackerL, JorisF, GuagliardoR, Van HoeckJ, MerckxP, Van CalenberghS, RamishettiS, et al. (2020). Cationic amphiphilic drugs boost the lysosomal escape of small nucleic acid therapeutics in a nanocarrier-dependent manner. ACS Nano, 14:4774–4791.
29.
JorisF, De SmedtS and RaemdonckK. (2017). Small molecules convey big messages: boosting non-viral nucleic acid delivery with low molecular weight drugs. Nano Today, 16:14–29.
30.
OsbornM, AltermanJ, NikanM, CaoH, DidiotM, HasslerM, CoesA and Khvorova.A (2015). Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res, 43:8664.
31.
MillerC, WanW, SethP and Harris.E (2018). Endosomal escape of antisense oligonucleotides internalized by stabilin receptors is regulated by Rab5C and EEA1 during endosomal maturation. Nucleic Acid Ther, 28:86.
32.
De Waard SiebingaI, BlomD, GriffioenM, SchrierP, HoogendoornE, BeverstockG, DanenE and JagerM. (1995). Establishment and characterization of an uveal-melanoma cell line. Int J Cancer, 62:155–161.
33.
LuytenG, NausN, MooyC, HagemeijerA, Kan-MitchellJ, Van DrunenE, VuvevskiV, De JongP and LuiderT. (1996). Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int J Cancer, 66:380–387.
34.
KirchmaierS, LustK and Wittbrodt.J (2013). Golden GATEway cloning—a combinatorial approach to generate fusion and recombination constructs. PLoS One, 8:e76117.
35.
MaloN, HanleyJ, CerquozziS, PelletierJ and NadonR. (2006). Statistical practice in high-throughput screening data analysis. Nat Biotechnol, 24:167–175.
36.
ZhaoW, SachsenmeierK, ZhangL, SultE, HollingsworthR and YangH. (2014). A new bliss independence model to analyze drug combination data. J Biomol Screen, 19:817–821.
37.
SchmidtE, ClavarinoG, CeppiM and PierreP. (2009). SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods, 6:275–277.
38.
NicholasD, ProctorE, RavalF, IpB, HabibC, RitouE, GrammatopoulosT, SteenkampD, DoomsH, et al. (2017). Advances in the quantification of mitochondrial function in primary human immune cells through extracellular flux analysis. PLoS One, 12:e0170975–19.
39.
OchabaJ, PowersA, TrembleK, GreenleeS, PostN, MatsonJ, MacLeodA, GuoS and AghajanM. (2019). A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity. Nucleic Acids Res, 47:11284–11303.
40.
UritsI, SwansonD, SwettM, PatelA, BerardinoK, AmgalanA, BergerA, KassemH, KayeA and ViswanathO. (2020). A Review of Patisiran (ONPATTRO) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther, 9:301–315.
41.
PópuloH, LopesJ and SoaresP. (2012). The mTOR signalling pathway in human cancer. Int J Mol Sci, 13:1886–1918.
42.
HuaH, KongQ, ZhangH, WangJ, LuoT and JiangY. (2019). Targeting mTOR for cancer therapy. J Hematol Oncol, 12:1–19.
43.
MoritaM, PrudentJ, BasuK, GoyonV, KatsumuraS, HuleaL, PearlD, SiddiquiN, StrackS, et al. (2017). mTOR Controls Mitochondrial Dynamics and Cell Survival via MTFP1. Cell, 67:922–935.e5.
44.
ZhouY, PengY, TangH, HeX, WangZ, HuD and ZhouX. (2016). Autophagy induction contributes to GDC-0349 resistance in head and neck squamous cell carcinoma (HNSCC) cells. Biochem Biophys Res Commun, 477:174–180.
45.
PeiZ, BlackwoodE, LiuL, MalekS, BelvinM, KoehlerM, OrtwineD, ChenH, CohenF, et al. (2012). Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349. ACS Med Chem Lett, 4:103–107.
46.
ZabnerJ, FasbenderA, MoningerT, PoellingerK and WelshM. (1995). Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem, 270:18997–19007.
47.
KimT and Eberwine.J (2010). Mammalian cell transfection: the present and the future. Anal Bioanal Chem, 397:3173.
48.
CardarelliF, DigiacomoL, MarchiniC, AmiciA, SalomoneF, FiumeG, RossettaA, GrattonE, PozziD and CaraccioloG. (2016). The intracellular trafficking mechanism of Lipofectamine-based transfection reagents and its implication for gene delivery. Sci Rep, 6:1–8.
49.
ManN, ChenY, ZhengF, ZhouW and WenL. (2010). Induction of genuine autophagy by cationic lipids in mammalian cells. Autophagy, 6:449–454.
50.
RobertH, JennicaL, Jing-Hsiung JamesO and Wei-ChiangS. (2012). Effects of Lipofectamine 2000/siRNA complexes on autophagy in hepatoma cells. Mol Biotechnol, 51:1–8.
51.
ToozeS, AbadaA and ElazarZ. (2014). Endocytosis and autophagy: exploitation or cooperation? Cold Spring Harb Perspect Biol, 6:18358–18359.
52.
Birgisdottir Å and Johansen.T (2020). Autophagy and endocytosis—interconnections and interdependencies. J Cell Sci, 133:jcs228114.
53.
Jc LinP, Kee TamY and CullisPR. (2014). Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer. Clin Lipidol, 9:317–331.
54.
YamamotoY, LinP, BeraldiE, ZhangF, KawaiY, LeongJ, KatsumiH, FazliL, FraserR, CullisP and GleaveM. (2015). siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer. Clin Cancer Res, 21:4845–4855.
55.
XiongH, VeeduR and DiermeierS. (2021). Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci, 22:1–27.
56.
MillerC and Harris.E (2016). Antisense oligonucleotides: treatment strategies and cellular internalization. RNA Dis, 3:e1393.
57.
ShimoT, MaruyamaR and YokotaT. (2018). Designing effective antisense oligonucleotides for exon skipping. Methods Mol Biol, 1687:143–155.
58.
AgrawalN, DasaradhiP, MohmmedA, MalhotraP, BhatnagarR and MukherjeeS. (2003). RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev, 67:657–685.
59.
TallaridaR. (2012). Quantitative methods for assessing drug synergism. Genes Cancer, 2:1003–1008.
60.
BarreraN, MoralesB, TorresS and VillalónM. (2005). Principles: mechanisms and modeling of synergism in cellular responses. Trends Pharmacol Sci, 26:526–532.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
